Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Zuckerman Investment Group injected $521,000 into Amgen by scooping up 1,803 shares during the fourth quarter. A crowd of other investors also hopped aboard the Amgen train, with stakes both large and ...

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Led by positive growth for shares of Apple and Amgen, the Dow Jones Industrial Average is rallying Monday afternoon. The Dow Dow Jones Industrial Average is trading 508 points higher (1.3%), as shares ...

Pharmaceutical company Sandoz has filed a federal lawsuit accusing Amgen of orchestrating an illegal scheme to block biosimilar competition for its blockbuster arthritis drug Enbrel, resulting in ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...

Switzerland-based generic drug maker Sandoz said on Monday that it has filed an antitrust lawsuit against Amgen, Inc, (AMGN) ...

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

Swiss generic and biosimilar medicines firm Sandoz (SIX: SDZ) today announced it has filed an antitrust lawsuit in the USA ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim ...

Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market ...